Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Venous Embolism of Lower Extremities (Diagnosis) Acute DVT of Lower Extremity Acute Limb Ischemia Arterial Embolism and Thrombosis Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Chronic DVT of Lower Extremity DVT Deep Vein Thrombosis Leg Disease Embolism and Thrombosis LE ALI Lower Extremity Acute Limb Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Peripheral Arterial Disease Peripheral Vascular Diseases Thrombosis Thrombus in the Peripheral Venous Vasculature Vascular Diseases Venous Thrombosis

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

MedStar Health, Washington D.C., District of Columbia, United States

About this study

The Liberant Clinical Assessment is a multicenter, prospective per patient HCP recollection survey. Participating HCPs will document their individual case experience following routine utilization of Liberant in accordance with the approved device labeling. Individual use cases will be entered within 72 hours of device usage to identify periprocedural incidents of risk and evaluate device performance. At least 50 use cases will be collected and aggregated from at least 10 participating HCPs. This data collection is for a single point in time, with no patient follow-up. Individual HCP responses for each case will be aggregated by a third party vendor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:

Patient treated is age ≥ 22 years at the time of procedure
Use of Liberant in accordance with the device labeling within 72 hours of index procedure

Treatment and study plan

Liberant Thrombectomy System

Device

The Liberant thrombectomy system is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

Primary outcomes

Rate of Device related Serious Adverse Event at Index procedure

Time frame: Index Procedure

An Adverse Event that converted to Serious Adverse Event, involving the function of the subject device, or the presence of the device in the body, including events that are directly attributable to the Liberant Thrombectomy System
Rate of technical success at Index procedure

Time frame: Index procedure

Technical success: Successful introduction, delivery, aspiration of fresh, soft emboli or thrombi, and retrieval of the Liberant per the Instructions for Use (IFU) during the index procedure
Rate of Procedural Success at Index procedure

Time frame: Index procedure

Procedure success: Successful removal of fresh, soft emboli or thrombi and restoration of adequate blood flow, inclusive of all endovascular therapies during the index procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Hunt

CONTACT

[email protected]

Manasa Gudipally

CONTACT

[email protected]

763-514-4000

Sponsors and collaborators

Lead sponsor

Medtronic Endovascular

Industry

Registry information

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jan 13, 2026
Registry last updated: Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed